RxDoctor Payments DataLook up a doctor →

Weiqin Xu

Nurse Practitioner · Rosemead, CANPI 1154839058

Payments from drug & device makers

$39,260in general payments, 2019–2025

Across 1,423 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Johnson & Johnson$4K
  • AstraZeneca$4K
  • Incyte Corporation$2K
  • Pfizer$2K
  • Merck$2K
  • plus $22K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis108$3,789
Johnson & Johnson123$3,768
AstraZeneca(2 entities)99$3,552
Incyte Corporation104$2,209
Pfizer70$1,916
Merck70$1,862
GSK65$1,758
AbbVie48$1,229
Lilly USA, LLC47$1,125
Takeda Pharmaceuticals U.S.A., Inc.36$1,017
Astellas Pharma US Inc33$1,006
Bayer36$991
Sobi, Inc42$931
Seagen Inc.21$852
E.r. Squibb & Sons, L.L.C.36$813
Exelixis Inc.23$752
Gilead34$749
Eisai Inc.35$678
Karyopharm Therapeutics Inc.22$665
Bristol Myers Squibb27$576
Regeneron Healthcare Solutions, Inc.17$567
Sanofi17$513
Boehringer Ingelheim22$507
EMD Serono, Inc.21$466
Daiichi Sankyo Inc.41$449
Amgen15$441
Beigene USA, Inc.9$379
Beone Medicines USA, Inc.10$346
Stemline Therapeutics Inc.9$316
Secura Bio, Inc.2$278
Lantheus Medical Imaging, Inc.3$274
Array Biopharma Inc11$271
Sumitomo Pharma America, Inc.15$269
Genentech USA, Inc.11$269
Rigel Pharmaceuticals, Inc.10$262
Jazz Pharmaceuticals Inc.6$251
Deciphera Pharmaceuticals Inc.7$240
Mirati Therapeutics, Inc.10$234
Pharmacyclics LLC, An Abbvie Company9$231
Agios Pharmaceuticals, Inc.5$214
Blueprint Medicines Corporation9$204
Puma Biotechnology, Inc.7$182
Pharmaessentia USA Corporation7$164
Taiho Oncology, Inc.7$157
G1 Therapeutics, Inc.3$142
ADC Therapeutics America, Inc.5$131
Servier Pharmaceuticals LLC2$115
Tersera Therapeutics LLC4$99
Tolmar Pharmaceuticals, Inc.4$96
Morphosys, US Inc.5$92
Novocure Inc.6$89
Sun Pharmaceutical Industries Inc.3$89
Coherus Oncology, Inc.4$86
Progenics Pharmaceuticals, Inc.3$78
AVEO Pharmaceuticals, Inc.3$70
Recordati_rare_diseases_inc.3$60
Springworks Therapeutics, Inc.2$56
Immunogen, Inc.2$50
Syndax Pharmaceuticals, Inc.2$48
EUSA Pharma (US) LLC2$38

How this compares

$39,260 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$1,987
Medicare patients
15
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Rosemead

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →